Exelixis Climbs 21% on Positive Phase 3 Advanced Kidney Cancer Study Results:   Exelixis reached a new 52-week high price after the firm reported positive topline results from its Pivotal Phase 3 CheckMate -9ER trial.  $EXEL #cancer #healthcare #stocks